ATTD 2026: Review evidence from the Dexcom Global Registry on CGM use in non-insulin treated type 2 diabetes.
This resource is intended for educational purposes only for healthcare providers practicing in the United States. It does not constitute medical advice and is not a substitute for professional judgment or individualized patient care.
This 8-minute presentation reviews the importance of early treatment optimization in type 2 diabetes and highlights findings from the Dexcom Global Registry demonstrating the potential benefits of CGM in adults with non-insulin treated type 2 diabetes.
This presentation is part of the Transforming Diabetes Care:The Power of Dexcom CGM from Prediabetes to Insulin Therapy session recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) 2026 in Barcelona, Spain on March 13, 2026.
